Availability of Inhaled Insulin Promotes Greater Perceived Acceptance of Insulin Therapy in Patients With Type 2 Diabetes-Reference-Cited by-同舟云学术

Availability of Inhaled Insulin Promotes Greater Perceived Acceptance of Insulin Therapy in Patients With Type 2 Diabetes

Published:2005-02-01 Issue:2 Volume:28 Page:427-428
ISSN:0149-5992
Container-title:Diabetes Care
language:en
Short-container-title:

Author:

Freemantle Nick¹,Blonde Lawrence²,Duhot Didier³,Hompesch Marcus⁴,Eggertsen Robert⁵,Hobbs F.D. Richard¹,Martinez Luc³,Ross Stuart⁶,Bolinder Björn⁷,Stridde Elmar⁸

Affiliation:

1. Department of Primary Care & General Practice, University of Birmingham, Birmingham, U.K.

2. Ochsner Clinic Foundation, New Orleans, Louisiana

3. Société Française de Médecine Générale, Issy les Moulineaux, France

4. Profil Institute for Clinical Research, Chula Vista, California

5. Department of Primary Health Care, Göteborg University, Göteborg, Sweden

6. Faculty of Medicine, University of Calgary, Calgary, Alberta, Canada

7. Aventis Pharma, Bridgewater, New Jersey

8. Pfizer, Karlsruhe, Germany

Publisher

American Diabetes Association

Subject

Advanced and Specialized Nursing,Endocrinology, Diabetes and Metabolism,Internal Medicine

Link

https://diabetesjournals.org/care/article-pdf/28/2/427/666066/zdc00205000427.pdf

Reference7 articles.

1. Cefalu W, the Exubera Phase III Study Group: Mealtime rapid-acting inhaled insulin (Exubera) improves glycemic control in patients with type 2 diabetes failing combination oral agents: a 3-month, randomized, comparative trial (Abstract). Diabetologia 45:A260, 2002

2. Bélanger A, the Exubera Phase III Study Group: Efficacy and safety of inhaled insulin (Exubera) compared to subcutaneous insulin therapy in patients with type 2 diabetes: results of a 6-month, randomised, comparative trial (Abstract). Diabetologia 45:A260, 2002

3. Quattrin T, the Exubera Phase III Study Group: Efficacy and safety of inhaled insulin (Exubera) compared to conventional subcutaneous insulin therapy in patients with type 1 diabetes: results of a 6-month, randomised comparative trial (Abstract). Diabetologia 45:A260, 2002

4. Klonoff D: Inhaled insulin (Review). Diabetes Technol Ther 1:307–313, 1999

5. Skyler J, Cefalu W, Kourides I, Landschulz W, Balagtas C, Cheng S-L, Gelfand R: Efficacy of inhaled insulin in type 1 diabetes mellitus: a randomised proof-of-concept study. Lancet 357:331–335, 2001

Cited by 93 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Recent advancements on novel approaches of insulin delivery;Medicine in Novel Technology and Devices;2023-09

2. New Routes of Insulin for Diabetes Treatment;International Journal of Advanced Research in Science, Communication and Technology;2023-03-22

3. Genomic Variation Prediction: A Summary From Different Views;Frontiers in Cell and Developmental Biology;2021-11-25

4. A Review: The Prospect of Inhaled Insulin Therapy via Vibrating Mesh Technology to Treat Diabetes;International Journal of Environmental Research and Public Health;2020-08-10

5. Oral insulin: time to rewrite the textbooks;The Lancet Diabetes & Endocrinology;2019-03